/HMTXF
HMTXF Stock - Hemostemix Inc.
Healthcare|BiotechnologyOTC
$0.06+0.00%
+$0.00 (+0.00%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.86
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.07
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HMTXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.06 – $0.06
TARGET (TP)$0.07
STOP LOSS$0.05
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.85
52W High$0.28
52W Low$0.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-223 | $-495 | $-1,101 | $-2,448 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,979,000 | $-2,333,000 | $-3,273,142 | $-6,666,000 | $-4,876,456 |
| Net Income | $-2,616,000 | $-2,502,000 | $-5,235,000 | $-6,286,000 | $-7,768,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.03 | $-0.07 | $-0.11 | $-0.24 |
Company Overview
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HMTXFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 28, 2026 | — | — | — | — |
Q4 2025 | Nov 28, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 29, 2025 | — | $-0.00 | — | — |
Q2 2025 | May 30, 2025 | — | $-0.01 | — | — |
Q2 2025 | Apr 29, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 27, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 25, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 29, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 29, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 29, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q4 2022 | Nov 29, 2022 | — | $-0.01 | — | — |
Q3 2022 | Sep 26, 2022 | — | $-0.02 | — | — |
Q3 2022 | Aug 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HMTXF
What is HMTXF's current stock price?
Hemostemix Inc. (HMTXF) is currently trading at $0.06 per share. The stock has moved +0.00% today.
What is the analyst price target for HMTXF?
No analyst price targets are currently available for this stock.
What sector is Hemostemix Inc. in?
Hemostemix Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is HMTXF's market cap?
Hemostemix Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does HMTXF pay dividends?
No, Hemostemix Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLCS
Cell Source, Inc.
$0.50
Mkt Cap: $0.0B
DVHGF
Devonian Health Group Inc.
$0.07
Mkt Cap: $0.0B
HOOK
HOOKIPA Pharma Inc.
$0.88
Mkt Cap: $0.0B
IMUC
EOM Pharmaceuticals Holdings, Inc.
$0.15
Mkt Cap: $0.0B
INTI
Inhibitor Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
LVCLF
Algorae Pharmaceuticals Limited
$0.00
Mkt Cap: $0.0B
NYMXF
Nymox Pharmaceutical Corporation
$0.07
Mkt Cap: $0.0B
OXBOF
Oxford BioDynamics Plc
$0.00
Mkt Cap: $0.0B
QPTFF
Quest PharmaTech Inc.
$0.01
Mkt Cap: $0.0B
SRBCF
Sirona Biochem Corp.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to HMTXF for comparison